C4 Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
CCCC$3.00-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows used in operating activities: | ||
| Net loss | $(105,316) | $(132,493) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Stock-based compensation expense | 29,662 | 27,235 |
| Depreciation and amortization | 1,818 | 1,880 |
| Reduction in carrying amount of right-of-use asset | 6,421 | 6,159 |
| Accretion of premium on marketable securities | (5,396) | (3,784) |
| Amortization of debt discount—related party | — | 405 |
| Loss on early extinguishment of debt | — | 621 |
| Other | 6 | 77 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 8,697 | (10,327) |
| Prepaid expenses and other current and long-term assets | (4,328) | 2,723 |
| Accounts payable | (119) | 273 |
| Accrued expenses and other current liabilities | (1,267) | 1,316 |
| Operating lease liability | (5,219) | (4,695) |
| Deferred revenue | 9,884 | 3,772 |
| Net cash used in operating activities | (65,157) | (106,838) |
| Cash flows provided by investing activities: | ||
| Proceeds from maturities of marketable securities | 233,231 | 289,955 |
| Purchase of marketable securities | (284,321) | (129,898) |
| Purchases of property and equipment | (180) | (1,708) |
| Net cash (used in) provided by investing activities | (51,270) | 158,349 |
| Cash flows provided by financing activities: | ||
| Proceeds from issuance of common stock pursuant to the at-the-market equity program, net | 24,370 | 57,673 |
| Proceeds from issuance of common stock pursuant to the Betta Pharma Stock Purchase Agreement | 20,000 | — |
| Payment of long-term debt − related party | — | (12,500) |
| Proceeds from exercises of stock options | 778 | 58 |
| Payments for repurchase of common stock for tax withholding | (194) | (110) |
| Other | 382 | 368 |
| Net cash provided by financing activities | 45,336 | 45,489 |
| Net change in cash, cash equivalents and restricted cash | (71,091) | 97,000 |
| Cash, cash equivalents and restricted cash at beginning of period | 130,033 | 33,033 |
| Cash, cash equivalents and restricted cash at end of period | $58,942 | $130,033 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash, cash equivalents and restricted cash at end of year | $58,942 | $130,033 |
| Less: restricted cash | (3,443) | (3,443) |
| Cash and cash equivalents at end of the year | $55,499 | $126,590 |
(in thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Supplemental disclosure of cash flow information: | ||
| Deferred revenue in accounts receivable | $— | $10,000 |
| Cash paid for interest - related party | $— | $990 |
| Cash paid for income taxes | $— | $1,003 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Capital expenditures in accounts payable and accrued expenses | $— | $18 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.